Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.

× No keyword cloud information.

11 in total

1. Cannabinoids and value-based decision making: implications for neurodegenerative disorders.

Authors: Angela M Lee; Erik B Oleson; Leontien Diergaarde; Joseph F Cheer; Tommy Pattij
Journal: Basal Ganglia Date: 2012-07-28

Review 2. Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.

Authors: Joyce M Richey; Orison Woolcott
Journal: Curr Diab Rep Date: 2017-09-14 Impact factor: 4.810

Review 3. New horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolism.

Authors: L Cristino; L Palomba; V Di Marzo
Journal: Int J Obes Suppl Date: 2014-07-08

4. Synthesis of S-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-(methyl-d₃ )butanamide-d₅ , octadeuterated JD5037.

Authors: Malliga R Iyer; Resat Cinar; Nathan J Coffey; Robert J Chorvat; George Kunos
Journal: J Labelled Comp Radiopharm Date: 2017-08-02 Impact factor: 1.921

5. A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects.

Authors: Tiziana Bisogno; Anu Mahadevan; Roberto Coccurello; Jae Won Chang; Marco Allarà; Yugang Chen; Giacomo Giacovazzo; Aron Lichtman; Benjamin Cravatt; Anna Moles; Vincenzo Di Marzo
Journal: Br J Pharmacol Date: 2013-06 Impact factor: 8.739

Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.

1. Cannabinoids and value-based decision making: implications for neurodegenerative disorders.

Review 2. Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.

Review 3. New horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolism.

4. Synthesis of S-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-(methyl-d₃ )butanamide-d₅ , octadeuterated JD5037.

5. A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects.

Review 6. The unrelenting fall of the pharmacological treatment of obesity.

7. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.

Review 8. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Review 9. Endocannabinoids in Body Weight Control.

10. Harveian Oration 2016: Some observations on the causes and consequences of obesity.

Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.

1. Cannabinoids and value-based decision making: implications for neurodegenerative disorders.

Review 2. Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases.

Review 3. New horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolism.

4. Synthesis of S-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-(methyl-d3 )butanamide-d5 , octadeuterated JD5037.

5. A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects.

Review 6. The unrelenting fall of the pharmacological treatment of obesity.

7. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.

Review 8. Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?

Review 9. Endocannabinoids in Body Weight Control.

10. Harveian Oration 2016: Some observations on the causes and consequences of obesity.

4. Synthesis of S-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-(methyl-d₃ )butanamide-d₅ , octadeuterated JD5037.